| Literature DB >> 25802333 |
Dan Ma1, Qin Fang2, Ping Wang3, Rui Gao3, Weibing Wu3, Tangsheng Lu4, Lu Cao4, Xiuying Hu3, Jishi Wang5.
Abstract
Resistance toward imatinib (IM) and other BCR/ABL tyrosine kinase inhibitors remains troublesome in the treatment of advanced stage chronic myeloid leukemia (CML). The aim of this study was to estimate the reversal effects of down-regulation of Na(+)/H(+) exchanger 1 (NHE1) on the chemoresistance of BCR-ABL-positive leukemia patients' cells and cell lines. After treatment with the specific NHE1 inhibitor cariporide to decrease intracellular pH (pHi), the heme oxygenase-1 (HO-1) levels of the K562R cell line and cells from IM-insensitive CML patients decreased. HO-1, as a Bcr/Abl-dependent survival molecule in CML cells, is important for the resistance to tyrosine kinase inhibitors in patients with newly diagnosed CML or IM-resistant CML. Silencing PKC-β and Nrf-2 or treatment with inhibitors of p38 pathways obviously blocked NHE1-induced HO-1 expression. Furthermore, treatment with HO-1 or p38 inhibitor plus IM increased the apoptosis of the K562R cell line and IM-insensitive CML patients' cells. Inhibiting HO-1 enhanced the activation of caspase-3 and poly(ADP-ribose) polymerase-1. Hence, the results support the anti-apoptotic role of HO-1 induced by NHE1 in the K562R cell line and IM-insensitive CML patients and provide a mechanism by which inducing HO-1 expression via the PKC-β/p38-MAPK pathway may promote tumor resistance to oxidative stress.Entities:
Keywords: Na+/H+ ion exchanger 1; chronic myelogenous leukemia (CML); drug resistance; heme oxygenase; imatinib resistance; p38 MAPK; p38/mitogen-activated protein kinase; protein kinase C (PKC)
Mesh:
Substances:
Year: 2015 PMID: 25802333 PMCID: PMC4432277 DOI: 10.1074/jbc.M114.626960
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157